Tocagen (NASDAQ:TOCA) was downgraded by Cantor Fitzgerald from an “overweight” rating to a “neutral” rating in a note issued to investors on Thursday, Marketbeat reports.

A number of other research firms have also recently weighed in on TOCA. Citigroup assumed coverage on Tocagen in a report on Thursday, May 30th. They issued a “buy” rating for the company. Leerink Swann set a $5.00 target price on Tocagen and gave the company a “hold” rating in a research report on Wednesday, May 22nd. Robert W. Baird lowered Tocagen from an “outperform” rating to a “neutral” rating in a research report on Thursday. HC Wainwright reaffirmed a “buy” rating on shares of Tocagen in a research report on Friday, August 9th. Finally, Zacks Investment Research lowered Tocagen from a “buy” rating to a “hold” rating in a research report on Wednesday, September 4th. Ten investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Tocagen has an average rating of “Hold” and an average target price of $10.62.

NASDAQ TOCA opened at $1.03 on Thursday. The stock has a market cap of $22.23 million, a PE ratio of -0.42 and a beta of 4.07. Tocagen has a fifty-two week low of $0.73 and a fifty-two week high of $15.80. The business has a 50 day moving average price of $4.26 and a two-hundred day moving average price of $7.23. The company has a quick ratio of 4.21, a current ratio of 4.21 and a debt-to-equity ratio of 0.86.

Tocagen (NASDAQ:TOCA) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.72) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.76) by $0.04. The firm had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $0.50 million. Tocagen had a negative return on equity of 115.81% and a negative net margin of 300.42%. Sell-side analysts anticipate that Tocagen will post -2.69 EPS for the current fiscal year.

Several institutional investors and hedge funds have recently made changes to their positions in TOCA. Bank of America Corp DE raised its position in shares of Tocagen by 28.6% in the 4th quarter. Bank of America Corp DE now owns 14,584 shares of the company’s stock valued at $120,000 after purchasing an additional 3,240 shares in the last quarter. Creative Planning acquired a new position in shares of Tocagen in the 1st quarter valued at approximately $117,000. BNP Paribas Arbitrage SA raised its position in shares of Tocagen by 72,350.0% in the 1st quarter. BNP Paribas Arbitrage SA now owns 4,347 shares of the company’s stock valued at $47,000 after purchasing an additional 4,341 shares in the last quarter. Rhumbline Advisers raised its position in shares of Tocagen by 9.4% in the 1st quarter. Rhumbline Advisers now owns 25,491 shares of the company’s stock valued at $277,000 after purchasing an additional 2,188 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its position in shares of Tocagen by 19.0% in the 1st quarter. JPMorgan Chase & Co. now owns 453,391 shares of the company’s stock valued at $4,929,000 after purchasing an additional 72,539 shares in the last quarter. 35.43% of the stock is currently owned by institutional investors.

Tocagen Company Profile

Tocagen Inc, a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells.

Further Reading: Mutual Funds

Analyst Recommendations for Tocagen (NASDAQ:TOCA)

Receive News & Ratings for Tocagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen and related companies with MarketBeat.com's FREE daily email newsletter.